Abstract 5529
Background
The treatment of mCRPC is a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
Methods
At data analysis 03/19 18 patients (pts) underwent Ac-225-PSMA-617 RLT between 10/17 and 12/18. All pts had previously received second line antihormonal treatment and 17/18 pts taxane based chemotherapy. All pts had shown progression after Lu-177-PSMA therapy (median 2 cycles). High PSMA-expression of the tumor lesions in PSMA-PET/CT before Ac-225-PSMA-617 was mandatory. Pts were treated at 8 weekly intervals until progression or intolerable side effects. Prostate-specific antigen (PSA) and blood cell count were measured every 2-3 weeks. We report updated data of hematological and non-hematological side effects, biochemical response and a subgroupanalysis.
Results
A total of 36 cycles of Ac-225-PSMA-617 (median dose 8 MBq, range 4,4–12.8) were applied. 7 pts received only 1 cycle, 5 pts 2 cycles, 5 pts 3 cycles and 1 patient 4 cycles. Baseline PSA was 822 ng/ml (range 49–4073). ECOG score was grade 0, 1 and 2 in 3, 13 and 2 pts. 15/18 pts showed any PSA-decline, 5/18 a PSA-decline of more than 50% and 3 pts no PSA-decline at any time. 6 weeks after treatment 12/18 showed any PSA decline and 4/18 a PSA-decline of > 50%. Grade 1 xerostomia occurred in 17 and grade 2 in 1 patient. 6/18 pts (33%) requested to stop treatment due to xerostomia. 2 pts developed grade 2 renal insufficiency, 5 pts grade 3-4 anemia, 2 pts grade 3-4 thrombocytopenia and 2 pts 3-4 leucopenia. 7/18 pts died during the observation period (median overall survival 9,6 months). The PSA-progression free survival was 1,3 months. In a subgroupanalysis of 9 pts with a rapid progression under a previous Lu-177-PSMA treatment 7 pts achieved any PSA-decline and 4 pts a decline of more than 50%.
Conclusions
In this small cohort Ac-225-PSMA-617 RLT showed antitumor effect in mCRPC after Lu-177-PSMA failure even after rapid tumour progression. However, treatment had to be stopped in one third of the pts due to xerostomia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract